Gary A. Lyons, Director at Travere Therapeutics, Inc. (TVTX), sold 80,000 shares at $15.15 ($1.2M) on 2024-10-04, disclosed to the SEC on 2024-10-04.
Scheduled sale ($1.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.35 | 21,179 | $304K | 25.8% |
| 2 | $14.35 | 21,179 | $304K | 25.8% |
| 3 | $15.15 | 18,821 | $285K | 24.2% |
| 4 | $15.15 | 18,821 | $285K | 24.2% |
| Total | $14.73 avg | 80,000 | $1.2M | 100% |
| Filing → |
| NBIX | SELL | 2025-12-04 | $2.3M | — | Filing → |
| NBIX | SELL | 2024-08-15 | $3.5M | — | Filing → |
| NBIX | SELL | 2024-07-18 | $279K | — | Filing → |